Department of Plastic and Reconstructive and Aesthetic Surgery, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Sapienza University of Rome, Via Tiburtina 443, 00159, Rome, Italy.
Aesthetic Plast Surg. 2014 Feb;38(1):192-198. doi: 10.1007/s00266-013-0252-8. Epub 2013 Dec 13.
Tuberous sclerosis, an autosomal dominant neurocutaneous syndrome seen in approximately 1 in 6,000 people worldwide, is characterized by the appearance of hamartomas in multiple organs. The classic clinical triad consists of angiofibromas, epilepsy, and developmental delay. Dermatologic disorder is one of the main characteristics. Angiofibromas, a common form of presentation, causes significant cosmetic and medical problems. The current treatment for skin lesions is laser therapy. The carbon dioxide (CO2) laser has been used satisfactorily in treating these lesions, but several studies have demonstrated a high percentage of recurrences. Erbium:yttrium-aluminum-garnet (YAG) laser treatment has been used to resurface skin abnormalities in patients with dermatologic conditions. The dye laser as an alternative uses the principles of selective photothermolysis and is very effective in treating the vascular component of tuberous sclerosis. The use of all these lasers to treat skin lesions in patients affected by tuberous sclerosis has never been described in the literature.
A retrospective study, conducted from 2007 to May 2013, investigated 13 patients who had tuberous sclerosis treated with an erbium:YAG/CO2/dye laser combination.
All the patients showed great improvement of their skin lesions. The results were evident immediately after the first treatment. No patient experienced complications or recurrence.
The combined use of the erbium:YAG/Dye/CO2 laser is a safe and effective treatment for skin lesions in patients affected by tuberous sclerosis.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
结节性硬化症是一种常染色体显性遗传的神经皮肤综合征，全球每 6000 人中约有 1 人患病，其特征是多个器官出现错构瘤。经典的临床三联征包括血管纤维瘤、癫痫和发育迟缓。皮肤疾病是主要特征之一。血管纤维瘤是常见的表现形式，会导致严重的美容和医疗问题。目前，皮肤病变的治疗方法是激光治疗。二氧化碳（CO2）激光已成功用于治疗这些病变，但多项研究表明复发率较高。铒：钇铝石榴石（YAG）激光已用于治疗皮肤科疾病患者的皮肤异常。染料激光作为替代方法，利用选择性光热分解的原理，在治疗结节性硬化症的血管成分方面非常有效。目前尚未有文献报道使用所有这些激光治疗患有结节性硬化症的患者的皮肤病变。
这是一项回顾性研究，于 2007 年至 2013 年 5 月进行，调查了 13 名患有结节性硬化症的患者，他们接受了铒：YAG/CO2/染料激光联合治疗。
所有患者的皮肤病变均有明显改善。第一次治疗后立即出现效果。没有患者出现并发症或复发。
联合使用铒：YAG/染料/CO2 激光是治疗结节性硬化症患者皮肤病变的一种安全有效的方法。
证据水平 V：本杂志要求作者为每篇文章分配一个证据水平。如需全面了解这些循证医学评级，请参考目录或在线作者指南 www.springer.com/00266 。
